Skip to main content
VYNE Therapeutics Inc. logo

VYNE Therapeutics Inc. — Investor Relations & Filings

Ticker · VYNE ISIN · US92941V1008 US Manufacturing
Open in API
Filings indexed 608 across all filing types
Latest filing 2022-03-17 Annual Report
Country US United States of America
Listing US VYNE

About VYNE Therapeutics Inc.

https://vynetherapeutics.com/

VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company's primary objective is to address unmet medical needs by advancing a pipeline of novel drug candidates. VYNE's approach centers on innovating beyond traditional assumptions to find improved solutions for patients with complex inflammatory and immunological diseases.

Recent filings

Filing Released Lang Actions
10-K
Annual Report FY 2021
2022-03-17 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and states that a press release announcing financial results for the year ended December 31, 2021, is furnished as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references a press release. The length is 3777 characters, which is relatively short and consistent with a current report filing rather than a full annual or quarterly report. The document is not the full Annual Report (10-K) or Interim Report (IR), nor is it a certification or proxy statement. It is a current report announcing financial results, which aligns with the definition of an Earnings Release (ER) filing type, as it is the initial announcement of periodical financial results (key highlights only). Therefore, the correct classification is Earnings Release (ER).
2022-03-17 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 15, 2022, which is a current report used to announce major events that shareholders should know about. The content includes a detailed description of a material definitive agreement related to a purchase agreement with Lincoln Park Capital Fund, LLC, involving potential sales of common stock and registration rights. Additionally, it announces the appointment of a new Chief Financial Officer. The Form 8-K is not an annual or quarterly report, nor is it a transcript, proxy, or earnings release. It primarily reports a capital financing agreement and a management change. According to the filing definitions, announcements of financing activities fall under Capital/Financing Update (CAP), and announcements of changes in senior management fall under Board/Management Information (MANG). Since both types of information are present, but the primary and detailed focus is on the financing agreement, the best classification is Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA).
2022-03-15 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a securities offering. It details the issuance and sale of common stock, including terms of the purchase agreement with Lincoln Park Capital Fund, use of proceeds, risk factors, and other offering details. It is not a financial report, earnings release, or management discussion, but rather a capital raising disclosure document. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes. The document length is substantial and contains detailed offering information, confirming it is not merely an announcement or a brief notice.
2022-03-15 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report under the Securities Exchange Act of 1934. The content focuses on an update regarding an investor presentation that has been revised and is available on the company's website. It includes information about clinical trial timelines and preclinical data but does not contain actual financial statements or detailed financial analysis. The document explicitly states that the information is being furnished and not filed, indicating it is an announcement rather than the report itself. The length of the document is 4286 characters, which is relatively short and consistent with an announcement rather than a full report. The key content is about an updated investor presentation used for investor meetings and conferences, which aligns with the category of Investor Presentation (IP). Therefore, the most appropriate classification is Investor Presentation (IP).
2022-03-08 English
FORM 8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 7, 2022. It includes a press release about positive preclinical data for a drug candidate, attached as an exhibit. The document is short (3410 characters) and primarily serves as an announcement of an event and the attached press release. There are no financial statements or detailed financial data presented. This fits the definition of a Regulatory Filing (RNS), which is a general regulatory announcement and a fallback category for filings that do not fit other specific categories. It is not an Annual Report, Earnings Release, or any other detailed financial or management report. Therefore, the correct classification is Regulatory Filings (RNS).
2022-03-07 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.